Ruxolitinib in et: Not all mpn are equal

Abstract

In this issue of Blood, Harrison et al report the results of the first randomized trial comparing ruxolitinib and best available therapy (BAT) in patients with essential thrombocythemia (ET) resistant or intolerant to hydroxycarbamide (HC). The study suggests that ruxolitinib is not superior to current second-line treatments for ET.1